ReviewAdvances in radiation oncology2026
Historical Review of the Role of Indirect Cell Death in High-Dose Per Fraction Radiation Therapy.
Review in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- Targeting Tumour Heterogeneity through sequential timing of anti-hallmark combination therapies -a hypothesis for implementation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to elaborate and further establish that indirect cell death secondary to vascular injury and stimulation of antitumor immunity plays a role in the tumor response to high-dose per fraction radiation therapy. Methods and Materials: We reviewed literature available from the National Library of Medicine on the indirect death of tumor cells caused by high-dose per fraction irradiation in experimental tumors and human tumors. We then examined the implications of indirect/additional cell death in applying the LQ (Linear Quadratic) model for high-dose per fraction radiation therapy of human tumors. Results: We found that numerous preclinical and clinical studies reported over the last 100 years clearly indicated that high-dose per fraction radiation therapy induces indirect tumor cell death by causing vascular damage and stimulating the immune system to varying degrees. On the other hand, a handful of studies have been reported that failed to observe significant indirect tumor cell death after high-dose per fraction irradiation. The LQ and associated models may be applicable to certain clinical situations, yet the inherent flaw of the LQ model overestimating cell death as the fraction dose increases is likely accommodated by the additional amount of indirect tumor cell death that occurs at these higher doses. Furthermore, the indirect effects of immune system stimulation are not accounted for by the LQ or other models. Conclusions: Indirect tumor cell death due to tumor vascular injury from radiation exposure has been observed over the last ∼100 years. Vascular damage as well as stimulation of antitumor immunity contribute significantly to the response of tumors to many, if not all, high-dose per fraction radiation therapy regimens.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.